文献速递认知障碍与痴呆神经重症与神经感染

阿尔茨海默病血浆生物标志物在朊蛋白病中的表现

Performance of Alzheimer Disease Plasma Biomarkers in Patients With Prion Diseases.
PubMed 文献 · Neurology · 2026-07-13

本研究基于英国国家朊蛋白病诊所前瞻性队列,分析278人血浆标志物,发现p-tau217和p-tau181在阿尔茨海默病与朊蛋白病中均升高,单一p-tau217异常不足以区分二者。血浆NfL/p-tau217比值区分散发性克雅病与散发性阿尔茨海默病的AUC达0.996,验证队列AUC为0.986,可作为怀疑朊蛋白病的提示信号。

要点

  • 阿尔茨海默病与朊蛋白病均可出现血浆p-tau217和p-tau181升高,单凭p-tau217异常诊断AD有误诊朊蛋白病风险。
  • 血浆NfL/p-tau217比值区分散发性克雅病与散发性AD的AUC为0.996,验证队列为0.986。
  • 当临床怀疑朊蛋白病时,NfL/p-tau217比值可作为提示信号辅助鉴别。

核心结论

  • 血浆p-tau217和p-tau181在AD和朊蛋白病中均升高,单一p-tau血浆标志物异常诊断AD可能将朊蛋白病误诊为AD。
  • 血浆NfL/p-tau217比值可近乎完美区分散发性CJD与散发性AD,可作为怀疑朊蛋白病的提示信号。

研究设计与样本

  • 前瞻性队列研究,纳入英国国家朊蛋白病诊所278人共345份样本,平均年龄58岁(SD 13.5),女性占48.2%。
  • 主要分析包括204例朊蛋白病(121例散发性CJD、11例医源性CJD、9例变异型CJD、47例缓慢进展遗传性朊蛋白病、16例快速进展遗传性朊蛋白病)、33例AD和41例健康对照。
  • 验证研究在不同实验室分析32例散发性AD和35例散发性CJD的连续样本,平均年龄65.0岁(SD 6.4),女性占56.7%。

主要发现

  • 区分无AD共病理的朊蛋白病与散发性AD时,p-tau217的AUC为0.605(95%CI 0.486-0.724),p-tau181的AUC为0.554(95%CI 0.446-0.661),GFAP的AUC为0.514(95%CI 0.389-0.640),均表现不佳。
  • Aβ42/40比值区分中度,AUC为0.770(95%CI 0.684-0.856)。
  • NfL/p-tau217比值的AUC为0.996(95%CI 0.987-1.000),NfL的AUC为0.988(95%CI 0.974-1.000),BD-tau/p-tau217比值的AUC为0.963(95%CI 0.929-0.996),BD-tau的AUC为0.934(95%CI 0.890-0.978),区分能力很好。
  • 验证研究中NfL/p-tau217比值区分散发性AD与散发性CJD的AUC为0.986(95%CI 0.966-1.000)。

关键数值与推荐

  • 阿尔茨海默病协会AD诊断标准提出,单一异常的高特异性血浆生物标志物(包括p-tau217)足以支持生物学诊断。
  • 本研究提供Class II证据表明血浆NfL/p-tau217可区分CJD患者与AD患者。

临床怎么用

  • 在临床表现可模拟AD的朊蛋白病患者中,不应仅凭单一p-tau217异常作出AD诊断。
  • 当临床存在朊蛋白病诊断可能性时,可检测血浆NfL/p-tau217比值作为提示信号,辅助鉴别朊蛋白病与AD。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Prion diseases can mimic Alzheimer disease (AD) at presentation. Alzheimer's Association AD diagnostic criteria suggest that a single abnormal highly specific plasma biomarker (including p-tau217) is sufficient for a biological diagnosis. We investigated the performance of AD plasma biomarkers in distinguishing AD and prion diseases. METHODS: We examined plasma biomarker data from patients with prion disease from a prospective cohort study recruited through the UK National Prion Clinic. Prion diseases were diagnosed clinically or with autopsy confirmation, and AD was diagnosed clinically with CSF biomarker confirmation. Plasma p-tau217, p-tau181, Aβ42/40 ratio, brain-derived tau (BD-tau), neurofilament light chain (NfL), and glial fibrillary acid protein (GFAP) were measured using Simoa. Median biomarker values in different groups were compared with Kruskal-Wallis test, and area under the receiver operating characteristic curve was used to compare accuracy in distinguishing prion diseases from sporadic AD (sAD). Lumipulse p-tau217 and NfL were measured in a validation study in a different laboratory. RESULTS: In the main study, we analyzed 345 samples from 278 individuals (mean age 58 [SD 13.5], 48.2% female), including 204 with prion diseases (121 sporadic Creutzfeldt-Jakob disease [CJD], 11 iatrogenic CJD, 9 variant CJD, 47 slow-progressing inherited prion disease (IPD) and 16 fast-progressing IPD), 33 with AD, and 41 healthy controls. For discriminating prion disease without AD copathology from sAD, none of p-tau217 (area under the curve [AUC] [95% CI] 0.605 [0.486-0.724]), p-tau181 (AUC 0.554 [0.446-0.661]), or GFAP (AUC 0.514 [0.389-0.640]) performed well. Aβ42/40 discriminated moderately (AUC 0.770 [0.684-0.856]). NfL/p-tau217 ratio (AUC 0.996 [0.987-1.000]), NfL (AUC 0.988 [0.974-1.000]), BD-tau/p-tau217 ratio (AUC 0.963 [0.929-0.996]), and BD-tau (AUC 0.934 [0.890-0.978]) discriminated very well. In an independent validation study, consecutive samples were analyzed from 32 patients with sAD and 35 patients with sporadic Creutzfeldt-Jakob disease (mean age 65.0 [SD 6.4], 56.7% female). NfL/p-tau217 again discriminated almost perfectly (AUC 0.986 [95% CI 0.966-1.000]). DISCUSSION: Plasma p-tau217 and p-tau181 are increased in both AD and prion diseases (regardless of burden of AD copathology). Diagnosing AD with a single abnormal p-tau plasma biomarker risks misdiagnosing prion diseases as AD. Plasma NfL/p-tau217 discriminates near-perfectly and could act as a flag to suspect prion diseases where this is a diagnostic possibility. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that plasma NfL/p-tau217 discriminates patients with CJD from those with AD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Coysh T, Laban R, Veleva E, et al. Performance of Alzheimer Disease Plasma Biomarkers in Patients With Prion Diseases. Neurology. 2026. PMID: 42441927. doi:10.1212/WNL.0000000000214712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。